1. Market Research
  2. > Pharmaceutical Market Trends
  3. > BioSante Pharmaceuticals, Inc. – Product Pipeline Review – 2013

BioSante Pharmaceuticals, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 84 pages

BioSante Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “BioSante Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the BioSante Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BioSante Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from BioSante Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- BioSante Pharmaceuticals, Inc. - Brief BioSante Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BioSante Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BioSante Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BioSante Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate BioSante Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BioSante Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BioSante Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BioSante Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BioSante Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

BioSante Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
BioSante Pharmaceuticals, Inc. Snapshot 6
BioSante Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
BioSante Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
BioSante Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
BioSante Pharmaceuticals, Inc. - Pipeline Products Glance 12
BioSante Pharmaceuticals, Inc. - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
BioSante Pharmaceuticals, Inc. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
BioSante Pharmaceuticals, Inc. - Drug Profiles 14
(dehydroepiandrosterone + estradiol + progesterone) 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
testosterone propionate 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
BioSante Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 18
BioSante Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 19
BioSante Pharmaceuticals, Inc. - Recent Pipeline Updates 20
BioSante Pharmaceuticals, Inc. - Dormant Projects 24
BioSante Pharmaceuticals, Inc. - Discontinued Pipeline Products 25
Discontinued Pipeline Product Profiles 25
CG-7870 25
BioSante Pharmaceuticals, Inc. - Company Statement 26
BioSante Pharmaceuticals, Inc. - Locations And Subsidiaries 29
Head Office 29
Other Locations and Subsidiaries 29
BioSante Pharmaceuticals, Inc., Recent Developments 30
BioSante Pharmaceuticals, Inc.- Press Release 30
Oct 26, 2010: BioSante Reports Positive LibiGel Data Monitoring Committee Recommendation 30
Oct 25, 2010: BioSante Reports Positive LibiGel Data Monitoring Committee Recommendation 31
Oct 18, 2010: BioSante Reaches Key LibiGel Safety Study Enrollment Target 32
Oct 11, 2010: BioSante Presents LibiGel Clinical Study Update At North American Menopause Society Meeting 33
Oct 04, 2010: BioSante To Present LibiGel Clinical Trial Update At North American Menopause Society Meeting 2010 34
Jul 13, 2010: BioSante Initiates LibiGel Study For Cognitive Function In Women 34
Jun 30, 2010: BioSante Announces Positive Results From Pill-Plus Oral Contraceptive Phase II Study 35
Jun 21, 2010: BioSante Pharmaceuticals Says FDA Advisory Committee Recommendation Against Flibanserin Has No Impact On LibiGel 36
Jun 21, 2010: BioSante Reports Positive LibiGel Safety Data In Phase III Clinical Program 36
Jun 18, 2010: BioSante To Present LibiGel Safety Update At ENDO Annual Meeting 37
Feb 18, 2010: BioSante Pharmaceuticals To Present LibiGel Clinical Update At ISSWSH Conference 37
Financial Deals Landscape 38
BioSante Pharmaceuticals, Inc., Deals Summary 38
BioSante Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deal Details 40
Asset Transactions 40
BioSante Acquires Elestrin Royalty From Azur Pharma 40
BioSante Pharma Reacquires Elestrin From Nycomed 41
Partnerships 43
BioSante Pharma Signs An Agreement With PharmaSwiss 43
BioSante Pharma Signs An Agreement With Azur Pharma 44
BioSante Pharma Signs An Agreement With Pantarhei Bioscience 45
Merger 46
BioSante Pharma And Ani Pharma To Merge 46
BioSante Pharma Merges With Cell Genesys 48
Licensing Agreements 51
BioSante Pharma Enters Into Licensing Agreement With The John P. Hussman Foundation 51
BioSante Pharma Enters Into Licensing Agreement With Aduro BioTech 53
BioSante Pharma Enters Into Licensing Agreement With Cold Genesys 54
BioSante Pharma Enters Into Licensing Agreement With Medical Aesthetic 56
Equity Offering 57
BioSante Pharma Completes Private Placement Of Units For $3.5 Million 57
BioSante Pharma Completes Underwritten Public Offering Of Common Stock For $48 Million 59
BioSante Pharma Files Registration Statement For Public Offering Of $150 Million 61
BioSante Pharma Completes Registered Direct Offering Of Units For $25.1 Million 62
BioSante Pharma Completes Registered Direct Offering Of Units For $18 Million 65
BioSante Pharma Completes Registered Direct Offering Of $15 Million 67
BioSante Pharma Files Resiatration Statement For Public Offering Of $75 Million 69
BioSante Pharma Completed Registered Direct Offering Of $18 Million 71
BioSante Completes Public Offering Of $12 Million 73
BioSante Pharma Completes Private Placement Of $18.33 Million 75
Cell Genesys Completes Registered Direct Offering Of $60 Million 77
Cell Genesys Completes Private Placement Of $75 Million 79
Asset Transactions 81
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84



List of Tables

BioSante Pharmaceuticals, Inc., Key Information 6
BioSante Pharmaceuticals, Inc., Key Facts 6
BioSante Pharmaceuticals, Inc. - Pipeline by Indication, 2013 8
BioSante Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 9
BioSante Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 10
BioSante Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2013 11
BioSante Pharmaceuticals, Inc. - Phase III, 2013 12
BioSante Pharmaceuticals, Inc. - Phase II, 2013 13
BioSante Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 18
BioSante Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 19
BioSante Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 20
BioSante Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 24
BioSante Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2013 25
BioSante Pharmaceuticals, Inc., Other Locations 29
BioSante Pharmaceuticals, Inc., Deals Summary 38
BioSante Acquires Elestrin Royalty From Azur Pharma 40
BioSante Pharma Reacquires Elestrin From Nycomed 41
BioSante Pharma Signs An Agreement With PharmaSwiss 43
BioSante Pharma Signs An Agreement With Azur Pharma 44
BioSante Pharma Signs An Agreement With Pantarhei Bioscience 45
BioSante Pharma And Ani Pharma To Merge 46
BioSante Pharma Merges With Cell Genesys 48
BioSante Pharma Enters Into Licensing Agreement With The John P. Hussman Foundation 51
BioSante Pharma Enters Into Licensing Agreement With Aduro BioTech 53
BioSante Pharma Enters Into Licensing Agreement With Cold Genesys 54
BioSante Pharma Enters Into Licensing Agreement With Medical Aesthetic 56
BioSante Pharma Completes Private Placement Of Units For $3.5 Million 57
BioSante Pharma Completes Underwritten Public Offering Of Common Stock For $48 Million 59
BioSante Pharma Files Registration Statement For Public Offering Of $150 Million 61
BioSante Pharma Completes Registered Direct Offering Of Units For $25.1 Million 62
BioSante Pharma Completes Registered Direct Offering Of Units For $18 Million 65
BioSante Pharma Completes Registered Direct Offering Of $15 Million 67
BioSante Pharma Files Resiatration Statement For Public Offering Of $75 Million 69
BioSante Pharma Completed Registered Direct Offering Of $18 Million 71
BioSante Completes Public Offering Of $12 Million 73
BioSante Pharma Completes Private Placement Of $18.33 Million 75
Cell Genesys Completes Registered Direct Offering Of $60 Million 77
Cell Genesys Completes Private Placement Of $75 Million 79
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 81



List of Figures

BioSante Pharmaceuticals, Inc. - Pipeline by Indication, 2013 8
BioSante Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 9
BioSante Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 10
BioSante Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2013 11
BioSante Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 18
BioSante Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.